Global Naproxen Market

Naproxen Comprehensive Study by Type (Tablet, Capsule, Other), Application (Rheumatoid Arthritis, Gout, Other), Distribution Channels (Pharmaceutical Stores, Clinics, Others) Players and Region - Global Market Outlook to 2026

Naproxen Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Naproxen is an arylpropionic acid derivative from arylacetic acid class of medicines. It has analgesic, anti-inflammatory and antipyretic properties. It is unrelated to salicylates and the corticosteroid hormones. Factors such as increasing prevalence of gout and rheumatoid arthitis coupled with rising consumer spending on health conscious products will provide a positive scope for the product penetration during the forecasted timeframe. The major companies are adding more tablets in Asia-Pacific countries as these countries are focused on fastest-growing verticals for the cure of arthritis.This growth is primarily driven by Increasing prevalence of arthritis and gout diseases. and Rising Application for Relieving Joint Stiffness and Inflammation..

Globally, a noticeable market trend is evident Value-Oriented Consumers . The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Kirsch Pharma GmbH (Germany), Nhwa Pharmaceutical (China), Huazhong Pharma (Thailand), Divis Laboratories (India), Aurobindo (India), Tianxin Pharmaceutical (China), Teva (Israel), Charioteer Pharmaceutical (China) and Taj Pharmaceuticals Limited (India) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Increasing prevalence of arthritis and gout diseases.
  • Rising Application for Relieving Joint Stiffness and Inflammation.

Market Trend
  • Value-Oriented Consumers
  • Collaboration and Tie Up Of Leading Players

Restraints
  • High Cost Associated with Naproxen products
  • Side Effects Associated within naproxen Product Such as Nausea Etc.

Opportunities
Availability as Over the Counter forms Product. and Upsurge Demand Due to Prevention from Gastrointestinal Diseases.
Challenges
Stringent Government Rules and Regulations, Stiff Competition Between Major Players and Substitutes Available For Naproxen

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Naproxen Study Sheds Light on
— The Naproxen Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Naproxen industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Naproxen industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Tablet
  • Capsule
  • Other
By Application
  • Rheumatoid Arthritis
  • Gout
  • Other
By Distribution Channels
  • Pharmaceutical Stores
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of arthritis and gout diseases.
      • 3.2.2. Rising Application for Relieving Joint Stiffness and Inflammation.
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
      • 3.3.2. Stiff Competition Between Major Players
      • 3.3.3. Substitutes Available For Naproxen
    • 3.4. Market Trends
      • 3.4.1. Value-Oriented Consumers
      • 3.4.2. Collaboration and Tie Up Of Leading Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Naproxen, by Type, Application, Distribution Channels and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Naproxen (Value)
      • 5.2.1. Global Naproxen by: Type (Value)
        • 5.2.1.1. Tablet
        • 5.2.1.2. Capsule
        • 5.2.1.3. Other
      • 5.2.2. Global Naproxen by: Application (Value)
        • 5.2.2.1. Rheumatoid Arthritis
        • 5.2.2.2. Gout
        • 5.2.2.3. Other
      • 5.2.3. Global Naproxen by: Distribution Channels (Value)
        • 5.2.3.1. Pharmaceutical Stores
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Naproxen Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Naproxen (Price)
      • 5.3.1. Global Naproxen by: Type (Price)
  • 6. Naproxen: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Kirsch Pharma GmbH (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Nhwa Pharmaceutical (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Huazhong Pharma (Thailand)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Divis Laboratories (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Aurobindo (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Tianxin Pharmaceutical (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Charioteer Pharmaceutical (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Taj Pharmaceuticals Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Naproxen Sale, by Type, Application, Distribution Channels and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Naproxen (Value)
      • 7.2.1. Global Naproxen by: Type (Value)
        • 7.2.1.1. Tablet
        • 7.2.1.2. Capsule
        • 7.2.1.3. Other
      • 7.2.2. Global Naproxen by: Application (Value)
        • 7.2.2.1. Rheumatoid Arthritis
        • 7.2.2.2. Gout
        • 7.2.2.3. Other
      • 7.2.3. Global Naproxen by: Distribution Channels (Value)
        • 7.2.3.1. Pharmaceutical Stores
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Naproxen Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Naproxen (Price)
      • 7.3.1. Global Naproxen by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Naproxen: by Type(USD Million)
  • Table 2. Naproxen Tablet , by Region USD Million (2015-2020)
  • Table 3. Naproxen Capsule , by Region USD Million (2015-2020)
  • Table 4. Naproxen Other , by Region USD Million (2015-2020)
  • Table 5. Naproxen: by Application(USD Million)
  • Table 6. Naproxen Rheumatoid Arthritis , by Region USD Million (2015-2020)
  • Table 7. Naproxen Gout , by Region USD Million (2015-2020)
  • Table 8. Naproxen Other , by Region USD Million (2015-2020)
  • Table 9. Naproxen: by Distribution Channels(USD Million)
  • Table 10. Naproxen Pharmaceutical Stores , by Region USD Million (2015-2020)
  • Table 11. Naproxen Clinics , by Region USD Million (2015-2020)
  • Table 12. Naproxen Others , by Region USD Million (2015-2020)
  • Table 13. South America Naproxen, by Country USD Million (2015-2020)
  • Table 14. South America Naproxen, by Type USD Million (2015-2020)
  • Table 15. South America Naproxen, by Application USD Million (2015-2020)
  • Table 16. South America Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 17. Brazil Naproxen, by Type USD Million (2015-2020)
  • Table 18. Brazil Naproxen, by Application USD Million (2015-2020)
  • Table 19. Brazil Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 20. Argentina Naproxen, by Type USD Million (2015-2020)
  • Table 21. Argentina Naproxen, by Application USD Million (2015-2020)
  • Table 22. Argentina Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 23. Rest of South America Naproxen, by Type USD Million (2015-2020)
  • Table 24. Rest of South America Naproxen, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 26. Asia Pacific Naproxen, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Naproxen, by Type USD Million (2015-2020)
  • Table 28. Asia Pacific Naproxen, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 30. China Naproxen, by Type USD Million (2015-2020)
  • Table 31. China Naproxen, by Application USD Million (2015-2020)
  • Table 32. China Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 33. Japan Naproxen, by Type USD Million (2015-2020)
  • Table 34. Japan Naproxen, by Application USD Million (2015-2020)
  • Table 35. Japan Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 36. India Naproxen, by Type USD Million (2015-2020)
  • Table 37. India Naproxen, by Application USD Million (2015-2020)
  • Table 38. India Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 39. South Korea Naproxen, by Type USD Million (2015-2020)
  • Table 40. South Korea Naproxen, by Application USD Million (2015-2020)
  • Table 41. South Korea Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 42. Taiwan Naproxen, by Type USD Million (2015-2020)
  • Table 43. Taiwan Naproxen, by Application USD Million (2015-2020)
  • Table 44. Taiwan Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 45. Australia Naproxen, by Type USD Million (2015-2020)
  • Table 46. Australia Naproxen, by Application USD Million (2015-2020)
  • Table 47. Australia Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Naproxen, by Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Naproxen, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 51. Europe Naproxen, by Country USD Million (2015-2020)
  • Table 52. Europe Naproxen, by Type USD Million (2015-2020)
  • Table 53. Europe Naproxen, by Application USD Million (2015-2020)
  • Table 54. Europe Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 55. Germany Naproxen, by Type USD Million (2015-2020)
  • Table 56. Germany Naproxen, by Application USD Million (2015-2020)
  • Table 57. Germany Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 58. France Naproxen, by Type USD Million (2015-2020)
  • Table 59. France Naproxen, by Application USD Million (2015-2020)
  • Table 60. France Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 61. Italy Naproxen, by Type USD Million (2015-2020)
  • Table 62. Italy Naproxen, by Application USD Million (2015-2020)
  • Table 63. Italy Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 64. United Kingdom Naproxen, by Type USD Million (2015-2020)
  • Table 65. United Kingdom Naproxen, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 67. Netherlands Naproxen, by Type USD Million (2015-2020)
  • Table 68. Netherlands Naproxen, by Application USD Million (2015-2020)
  • Table 69. Netherlands Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 70. Rest of Europe Naproxen, by Type USD Million (2015-2020)
  • Table 71. Rest of Europe Naproxen, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 73. MEA Naproxen, by Country USD Million (2015-2020)
  • Table 74. MEA Naproxen, by Type USD Million (2015-2020)
  • Table 75. MEA Naproxen, by Application USD Million (2015-2020)
  • Table 76. MEA Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 77. Middle East Naproxen, by Type USD Million (2015-2020)
  • Table 78. Middle East Naproxen, by Application USD Million (2015-2020)
  • Table 79. Middle East Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 80. Africa Naproxen, by Type USD Million (2015-2020)
  • Table 81. Africa Naproxen, by Application USD Million (2015-2020)
  • Table 82. Africa Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 83. North America Naproxen, by Country USD Million (2015-2020)
  • Table 84. North America Naproxen, by Type USD Million (2015-2020)
  • Table 85. North America Naproxen, by Application USD Million (2015-2020)
  • Table 86. North America Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 87. United States Naproxen, by Type USD Million (2015-2020)
  • Table 88. United States Naproxen, by Application USD Million (2015-2020)
  • Table 89. United States Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 90. Canada Naproxen, by Type USD Million (2015-2020)
  • Table 91. Canada Naproxen, by Application USD Million (2015-2020)
  • Table 92. Canada Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 93. Mexico Naproxen, by Type USD Million (2015-2020)
  • Table 94. Mexico Naproxen, by Application USD Million (2015-2020)
  • Table 95. Mexico Naproxen, by Distribution Channels USD Million (2015-2020)
  • Table 96. Naproxen: by Type(USD/Units)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Naproxen: by Type(USD Million)
  • Table 107. Naproxen Tablet , by Region USD Million (2021-2026)
  • Table 108. Naproxen Capsule , by Region USD Million (2021-2026)
  • Table 109. Naproxen Other , by Region USD Million (2021-2026)
  • Table 110. Naproxen: by Application(USD Million)
  • Table 111. Naproxen Rheumatoid Arthritis , by Region USD Million (2021-2026)
  • Table 112. Naproxen Gout , by Region USD Million (2021-2026)
  • Table 113. Naproxen Other , by Region USD Million (2021-2026)
  • Table 114. Naproxen: by Distribution Channels(USD Million)
  • Table 115. Naproxen Pharmaceutical Stores , by Region USD Million (2021-2026)
  • Table 116. Naproxen Clinics , by Region USD Million (2021-2026)
  • Table 117. Naproxen Others , by Region USD Million (2021-2026)
  • Table 118. South America Naproxen, by Country USD Million (2021-2026)
  • Table 119. South America Naproxen, by Type USD Million (2021-2026)
  • Table 120. South America Naproxen, by Application USD Million (2021-2026)
  • Table 121. South America Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 122. Brazil Naproxen, by Type USD Million (2021-2026)
  • Table 123. Brazil Naproxen, by Application USD Million (2021-2026)
  • Table 124. Brazil Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 125. Argentina Naproxen, by Type USD Million (2021-2026)
  • Table 126. Argentina Naproxen, by Application USD Million (2021-2026)
  • Table 127. Argentina Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 128. Rest of South America Naproxen, by Type USD Million (2021-2026)
  • Table 129. Rest of South America Naproxen, by Application USD Million (2021-2026)
  • Table 130. Rest of South America Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 131. Asia Pacific Naproxen, by Country USD Million (2021-2026)
  • Table 132. Asia Pacific Naproxen, by Type USD Million (2021-2026)
  • Table 133. Asia Pacific Naproxen, by Application USD Million (2021-2026)
  • Table 134. Asia Pacific Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 135. China Naproxen, by Type USD Million (2021-2026)
  • Table 136. China Naproxen, by Application USD Million (2021-2026)
  • Table 137. China Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 138. Japan Naproxen, by Type USD Million (2021-2026)
  • Table 139. Japan Naproxen, by Application USD Million (2021-2026)
  • Table 140. Japan Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 141. India Naproxen, by Type USD Million (2021-2026)
  • Table 142. India Naproxen, by Application USD Million (2021-2026)
  • Table 143. India Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 144. South Korea Naproxen, by Type USD Million (2021-2026)
  • Table 145. South Korea Naproxen, by Application USD Million (2021-2026)
  • Table 146. South Korea Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 147. Taiwan Naproxen, by Type USD Million (2021-2026)
  • Table 148. Taiwan Naproxen, by Application USD Million (2021-2026)
  • Table 149. Taiwan Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 150. Australia Naproxen, by Type USD Million (2021-2026)
  • Table 151. Australia Naproxen, by Application USD Million (2021-2026)
  • Table 152. Australia Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 153. Rest of Asia-Pacific Naproxen, by Type USD Million (2021-2026)
  • Table 154. Rest of Asia-Pacific Naproxen, by Application USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 156. Europe Naproxen, by Country USD Million (2021-2026)
  • Table 157. Europe Naproxen, by Type USD Million (2021-2026)
  • Table 158. Europe Naproxen, by Application USD Million (2021-2026)
  • Table 159. Europe Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 160. Germany Naproxen, by Type USD Million (2021-2026)
  • Table 161. Germany Naproxen, by Application USD Million (2021-2026)
  • Table 162. Germany Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 163. France Naproxen, by Type USD Million (2021-2026)
  • Table 164. France Naproxen, by Application USD Million (2021-2026)
  • Table 165. France Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 166. Italy Naproxen, by Type USD Million (2021-2026)
  • Table 167. Italy Naproxen, by Application USD Million (2021-2026)
  • Table 168. Italy Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 169. United Kingdom Naproxen, by Type USD Million (2021-2026)
  • Table 170. United Kingdom Naproxen, by Application USD Million (2021-2026)
  • Table 171. United Kingdom Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 172. Netherlands Naproxen, by Type USD Million (2021-2026)
  • Table 173. Netherlands Naproxen, by Application USD Million (2021-2026)
  • Table 174. Netherlands Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 175. Rest of Europe Naproxen, by Type USD Million (2021-2026)
  • Table 176. Rest of Europe Naproxen, by Application USD Million (2021-2026)
  • Table 177. Rest of Europe Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 178. MEA Naproxen, by Country USD Million (2021-2026)
  • Table 179. MEA Naproxen, by Type USD Million (2021-2026)
  • Table 180. MEA Naproxen, by Application USD Million (2021-2026)
  • Table 181. MEA Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 182. Middle East Naproxen, by Type USD Million (2021-2026)
  • Table 183. Middle East Naproxen, by Application USD Million (2021-2026)
  • Table 184. Middle East Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 185. Africa Naproxen, by Type USD Million (2021-2026)
  • Table 186. Africa Naproxen, by Application USD Million (2021-2026)
  • Table 187. Africa Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 188. North America Naproxen, by Country USD Million (2021-2026)
  • Table 189. North America Naproxen, by Type USD Million (2021-2026)
  • Table 190. North America Naproxen, by Application USD Million (2021-2026)
  • Table 191. North America Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 192. United States Naproxen, by Type USD Million (2021-2026)
  • Table 193. United States Naproxen, by Application USD Million (2021-2026)
  • Table 194. United States Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 195. Canada Naproxen, by Type USD Million (2021-2026)
  • Table 196. Canada Naproxen, by Application USD Million (2021-2026)
  • Table 197. Canada Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 198. Mexico Naproxen, by Type USD Million (2021-2026)
  • Table 199. Mexico Naproxen, by Application USD Million (2021-2026)
  • Table 200. Mexico Naproxen, by Distribution Channels USD Million (2021-2026)
  • Table 201. Naproxen: by Type(USD/Units)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Naproxen: by Type USD Million (2015-2020)
  • Figure 5. Global Naproxen: by Application USD Million (2015-2020)
  • Figure 6. Global Naproxen: by Distribution Channels USD Million (2015-2020)
  • Figure 7. South America Naproxen Share (%), by Country
  • Figure 8. Asia Pacific Naproxen Share (%), by Country
  • Figure 9. Europe Naproxen Share (%), by Country
  • Figure 10. MEA Naproxen Share (%), by Country
  • Figure 11. North America Naproxen Share (%), by Country
  • Figure 12. Global Naproxen: by Type USD/Units (2015-2020)
  • Figure 13. Global Naproxen share by Players 2020 (%)
  • Figure 14. Global Naproxen share by Players (Top 3) 2020(%)
  • Figure 15. Global Naproxen share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Kirsch Pharma GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Kirsch Pharma GmbH (Germany) Revenue: by Geography 2020
  • Figure 19. Nhwa Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 20. Nhwa Pharmaceutical (China) Revenue: by Geography 2020
  • Figure 21. Huazhong Pharma (Thailand) Revenue, Net Income and Gross profit
  • Figure 22. Huazhong Pharma (Thailand) Revenue: by Geography 2020
  • Figure 23. Divis Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 24. Divis Laboratories (India) Revenue: by Geography 2020
  • Figure 25. Aurobindo (India) Revenue, Net Income and Gross profit
  • Figure 26. Aurobindo (India) Revenue: by Geography 2020
  • Figure 27. Tianxin Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 28. Tianxin Pharmaceutical (China) Revenue: by Geography 2020
  • Figure 29. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 30. Teva (Israel) Revenue: by Geography 2020
  • Figure 31. Charioteer Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 32. Charioteer Pharmaceutical (China) Revenue: by Geography 2020
  • Figure 33. Taj Pharmaceuticals Limited (India) Revenue, Net Income and Gross profit
  • Figure 34. Taj Pharmaceuticals Limited (India) Revenue: by Geography 2020
  • Figure 35. Global Naproxen: by Type USD Million (2021-2026)
  • Figure 36. Global Naproxen: by Application USD Million (2021-2026)
  • Figure 37. Global Naproxen: by Distribution Channels USD Million (2021-2026)
  • Figure 38. South America Naproxen Share (%), by Country
  • Figure 39. Asia Pacific Naproxen Share (%), by Country
  • Figure 40. Europe Naproxen Share (%), by Country
  • Figure 41. MEA Naproxen Share (%), by Country
  • Figure 42. North America Naproxen Share (%), by Country
  • Figure 43. Global Naproxen: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Kirsch Pharma GmbH (Germany)
  • Nhwa Pharmaceutical (China)
  • Huazhong Pharma (Thailand)
  • Divis Laboratories (India)
  • Aurobindo (India)
  • Tianxin Pharmaceutical (China)
  • Teva (Israel)
  • Charioteer Pharmaceutical (China)
  • Taj Pharmaceuticals Limited (India)
Select User Access Type

Key Highlights of Report


Aug 2021 218 Pages 54 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Naproxen Market Quantitative research analysis
Global Naproxen Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Naproxen market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Naproxen market are Kirsch Pharma GmbH (Germany), Nhwa Pharmaceutical (China), Huazhong Pharma (Thailand), Divis Laboratories (India), Aurobindo (India), Tianxin Pharmaceutical (China), Teva (Israel), Charioteer Pharmaceutical (China) and Taj Pharmaceuticals Limited (India), to name a few.
North America is dominating the Naproxen Market.

Know More About Global Naproxen Market Report?

Have a Query? Click Here

Other Related Reports

Erythromycin Comprehensive Study by Form (Gel, Tablet, Topical Solution, Ointment, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Therapeutic Indications (...
$ 3650
Dystonia Drugs Comprehensive Study by Route of Administration (Oral, Injectable), Drug Types (Capsules, Tablets, Other), Dystonias syndromes (Blepharospasm, Cervical dystonia, Cranial dystonia, Tardi...
$ 3750
Vertigo Drugs Comprehensive Study by Route of Administration (Oral, Injection), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Class (Anticholinergics, Antihistamines, Be...
$ 3650
Nano Colloidal Silver Comprehensive Study by Type (10ppm Colloidal Silver, 20ppm Colloidal Silver, 22ppm Colloidal Silver, 30ppm Colloidal Silver, Others), Application (Deodorant, Epidemic Prevention...
$ 3450
Psychotropic Drug Comprehensive Study by End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital pharmacies, Drug Stores, Retail Stores, E-Commerce), Drug Class (Anti-Depressants, Anti...
$ 3450
Amoxicillin Sodium Comprehensive Study by Type (Capsules, Tablets, Chewable Tablets, Powder), Application (Humans, Animals), Route of Administration (Injectable, Oral), Distribution Channel (Offline ...
$ 3350